-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target

Benzinga·09/09/2026 12:55:30
Listen to the news
Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.